- Perrigo to buy Elan Corp.
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Mylan launches generic version of Trilipix
- Roxane Labs' generic prostate drug gets tentative approval from FDA
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
ALLEGAN, Mich. — Drug maker Perrigo has launched a generic drug for treating problems of the scalp, the company said.
Perrigo announced the launch of clobetasol emulsion propionate foam in the 0.05% strength, a generic version of GlaxoSmithKline's Olux-E. The drug is used to treat moderate to severe dermatosis of the scalp.
As the first company to file a regulatory approval application for the drug, Perrigo is entitled to 180 days in which to compete exclusively with GlaxoSmithKline's version. The drug has annual sales of $38 million, according to Symphony Health Solutions.